Soni Zacharias, MD
Interventional Cardiology · Oklahoma City, OKNPI 1902947534
Payments from drug & device makers
Across 621 payments — averaging $20.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Boehringer Ingelheim$2K
- Amgen$1K
- Johnson & Johnson$1K
- Merck$1K
- E.r. Squibb & Sons, L.L.C.$791
- plus $5K from 29 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 46 | $1,692 |
| Boehringer Ingelheim | 60 | $1,521 |
| Amgen | 55 | $1,216 |
| Johnson & Johnson | 74 | $1,119 |
| Merck | 57 | $1,063 |
| E.r. Squibb & Sons, L.L.C. | 54 | $791 |
| Novartis | 48 | $727 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 53 | $726 |
| Novo Nordisk | 16 | $560 |
| Pfizer | 41 | $492 |
| Abiomed | 6 | $371 |
| Esperion Therapeutics, Inc. | 7 | $331 |
| Boston Scientific | 10 | $314 |
| Amarin Pharma, Inc. | 13 | $224 |
| Vifor Pharma, Inc. | 13 | $214 |
| Abbott | 7 | $148 |
| Daiichi Sankyo Inc. | 6 | $145 |
| Impulse Dynamics (USA) Inc. | 10 | $142 |
| Kestra Medical Technology Services, Inc. | 5 | $115 |
| Lexicon Pharmaceuticals, Inc. | 6 | $108 |
| Irhythm Technologies, Inc. | 6 | $104 |
| Sanofi-aventis U.S. LLC | 5 | $87 |
| Regeneron Healthcare Solutions, Inc. | 6 | $83 |
| Bayer | 3 | $58 |
| Philips North America LLC | 2 | $44 |
| Lundbeck LLC | 2 | $42 |
| Medtronic | 1 | $35 |
| Atricure, Inc. | 2 | $34 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Scpharmaceuticals Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Edwards Lifesciences | 1 | $13 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $13 |
| Lilly USA, LLC | 1 | $11 |
| Actelion Pharmaceuticals US, Inc. | 1 | $6 |
How this compares
$12,598 in reported general payments places this provider in the 60th percentile of 110 interventional cardiology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other interventional cardiology in Oklahoma City
- Naeem TahirkheliOklahoma City$8.6M
- Mohammad GhaniOklahoma City$1.8M
- George ChrysantOklahoma City$873K
- Usman BaberOklahoma City$736K
- Jeffrey SparlingOklahoma City$381K
- Thomas McGarryOklahoma City$153K
- Faisal LatifOklahoma City$129K
- Branislav SchifferdeckerOklahoma City$121K
- Mazen Abu-FadelOklahoma City$98K
- Dwayne SchmidtOklahoma City$79K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.